WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $4,834,398 | $3,399,729 | $4,420,286 | $3,993,119 |
| Dep. & Amort. | $1,437,054 | $1,169,376 | $800,674 | $481,783 |
| Deferred Tax | $0 | $0 | $0 | -$567,114 |
| Stock-Based Comp. | $1,215,587 | $1,274,051 | $1,296,759 | $531,923 |
| Change in WC | -$800,504 | -$896,345 | -$974,472 | -$963,326 |
| Other Non-Cash | -$1,469,278 | -$279,099 | -$1,574 | -$45,127 |
| Operating Cash Flow | $5,217,257 | $4,667,712 | $5,541,673 | $3,431,258 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,929,621 | -$4,045,574 | -$5,868,390 | -$6,523,114 |
| Net Acquisitions | $0 | $0 | -$131,485 | -$2,535,130 |
| Inv. Purchases | -$11,429,271 | -$15,083,019 | -$10,770,982 | -$59,300,120 |
| Inv. Sales/Matur. | $10,892,906 | $15,638,338 | $10,485,040 | $58,243,899 |
| Other Inv. Act. | $524,280 | $261,989 | $377,565 | $512,795 |
| Investing Cash Flow | -$3,941,706 | -$3,228,266 | -$5,908,252 | -$9,601,670 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $490,101 | -$818,450 | -$295,018 | -$146,826 |
| Stock Issued | $19,392 | $26,158 | $36,180 | $11,035,309 |
| Stock Repurch. | -$1,765,946 | -$916,916 | -$2,804,454 | -$2,517,115 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$1,493,738 | $3,670,371 | $471,700 | -$161,909 |
| Financing Cash Flow | -$2,750,191 | $1,961,163 | -$2,591,592 | $8,209,459 |
| Forex Effect | $83,983 | -$125,992 | $350,113 | -$131,502 |
| Net Chg. in Cash | -$1,390,657 | $3,274,617 | -$2,608,058 | $1,907,545 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $9,669,839 | $6,395,222 | $9,003,280 | $7,095,735 |
| End Cash | $8,279,182 | $9,669,839 | $6,395,222 | $9,003,280 |
| Free Cash Flow | $1,287,636 | $437,198 | -$326,717 | -$3,091,856 |